Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Pliant Therapeutics Inc (9PT.F)

Compare

2.8200

-0.0200

(-0.70%)

As of 9:59:02 AM GMT+1. Market Open.

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

As the U.S. stock market flirts with record highs, investors are keenly watching for opportunities that may not be immediately apparent in the headlines. Penny stocks, often representing smaller or newer companies, continue to intrigue those looking beyond established giants for potential growth. Despite their historical reputation as speculative bets, some penny stocks today boast robust financial health and present intriguing possibilities for investors seeking unique opportunities.

Simply Wall St. 5 days ago

BLDE

BLDEW

NAUT
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 9 days ago

PLRX
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company sai

PREMIUM
MT Newswires 10 days ago

PLRX
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

BioPharma Dive 10 days ago

BIIB

ABBV

NMRA
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial dataSOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial’s independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fib

GlobeNewswire 10 days ago

PLRX
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause to the enrollment, and dosing, of its Phase 2b BEACON trial based on the recommendation of the Data and Safety Monitoring Board. The news “portends a material fundamental setback for the program, either for reasons of safety or futile activity,” the analyst tells investors in a research note. The firm says that with little pipeline value beyond bexotogras

TipRanks 12 days ago

PLRX
Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

The company halted enrollment and dosing for its BEACON-IPF Phase 2b trial based on a recommendation from the DSMB.

GuruFocus.com 13 days ago

PLRX
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue. Patients currently enrolled in BEACON-IPF will remain in the trial. The move follows a prespecified data review and reco

Benzinga 13 days ago

PLRX
Pliant shares collapse as company halts fibrosis drug study

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, but doesn’t yet know what led to their decision.

BioPharma Dive 14 days ago

PLRX
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEAC

GlobeNewswire 16 days ago

PLRX
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, Ph.D., the Company’s newly appointed Chief Technical Officer, as a material inducement to her employment. The stock options that were granted are subject to an exercise price of $11.07 per share, which is equal to the closing price of t

GlobeNewswire last month

PLRX
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, pr

GlobeNewswire last month

PLRX
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Pliant’s web

GlobeNewswire last month

PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events. Evercore 7th Annual HealthCONx Conference Members of Pliant’s senior management will meet with investors on Tuesday, December 3, 2024.Citi 2024 Global Healthcare Conference Memb

GlobeNewswire 3 months ago

PLRX
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of clinical data at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) being held in San Diego, California. Bexotegrast,

GlobeNewswire 3 months ago

PLRX
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. “A highlight to this quarter’s progress wa

GlobeNewswire 3 months ago

PLRX
Pliant Therapeutics to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time at the Lotte New York Palace Hotel in New York, New York. Interested parties may access the live webcast of the fireside chat by visiting the Investor Relations’ Events &

GlobeNewswire 3 months ago

PLRX
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meet

GlobeNewswire 4 months ago

PLRX
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc

On September 24, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 3,059,411 shares of Pliant Therapeutics Inc (NASDAQ:PLRX), a notable player in the biopharmaceutical industry. This transaction, executed at a price of $11.33 per share, represents a new holding for the firm, emphasizing its strategic investment in the healthcare sector. The acquisition not only diversifies Paradigm Biocapital's portfolio but also underscores its commitment to investing in companies with groundbreaking medical therapies.

GuruFocus.com 4 months ago

PLRX
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company’s global medical

GlobeNewswire 4 months ago

PLRX

Performance Overview

Return	9PT.F	S&P 500
YTD	-77.97%	+2.24%
1-Year	-80.68%	+18.16%
3-Year	-63.38%	+40.21%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pliant Therapeutics Inc (9PT.F)

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Pliant shares collapse as company halts fibrosis drug study

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Performance Overview